PainReform Ltd (PRFX): Rasio rega marang dodolan
Despite its Israeli origin and associated geopolitical risks, PainReform Ltd. (PRFX) maintains stability through global partnerships. High demand for the PRF-110 oil-based formulation provides the company with pricing power in anesthesiology. The price-to-sales ratio on this GURU.Markets platform chart confirms market expectations, where the 0.80 mark serves as a key metric. This reinforces the commercialization potential of non-opioid analgesics and the developer's clinical successes.
%20Multiplikator%20P%2FS&width=1200&height=400&colorIndex=0&v=mwejrfjc.e5f-7d7lczk&start=20220704&end=20261113&filename=GURU_Markets_-_PRFX_-_PainReform-Ltd._-_PS-Multiple "PRFX - Multiplikator P/S PainReform Corp ing rentang 28.03.2026 - 13.11.2026 | 👁️GURU.Markets👁️")
Rincian metrik lan analitis perusahaan PainReform Limited (PRFX)
- rega saham lan konsensus proyeksi valuasi:
- data kapitalisasi bursa:
- indikator nilai aset resik miturut neraca:
- statistik kawajiban utang lan likuiditas:
Rasio Utang marang Ekuitas PainReform Ltd.|PRFX - Utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal PainReform Corp|PRFX - Gunggung utang perusahaan|Utang-utang marang nilai buku PainReform Limited|PRFX - Utang jangka dawa perusahaan|Kewajiban jangka cendhak PainReform|Likuiditas darurat painreform.com
- indikator profitabilitas perusahaan lan kelipatan valuasi:
PRFX - Bathi resik perusahaan|Penghasilan resik sing dikarepake PainReform Ltd.|PRFX - Rasio rega marang bathi|Prakiraan rega marang bathi PainReform Ltd|PRFX - Pangali rega marang bathi tumrap wutah|Nilai bisnis marang bathi operasional sadurunge panyusutan PainReform Limited|PRFX - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan PainReform|PRFX - Bathi resik saben saham sajrone 12 wulan pungkasan|Kacepetan wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan painreform.com|PRFX - Wutah bathi ing taun lumaku|Proyeksi kacepetan wutah bathi saben saham kanggo taun ngarep PainReform Ltd.
- rincian pendapatan lan dodolan emiten:
Analisis umum perusahaan:PRFX - painreform.com
The P/S multiple compares the current market capitalization of PainReform Ltd. (PRFX) to its annual revenue, determining the value of each unit of sales. By analyzing P/S volatility, an investor assesses business transparency, where the potential for implementing innovative PRF-110 analgesics to reduce opioid dependence directly impacts the market revaluation of assets and price action.
Perusahaan pesaing
HLN (haleon.com) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Kenvue KVUE|VRNA (Verona Pharma PLC) - Rasio rega marang dodolan|Jyong Biotech Corp - Multiplikator P/S|LGND - Multiplikator P/S|AMRX: Multiplikator P/S|PRGO - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Alvotech SA|Rasio kapitalisasi marang pendapatan LQDA (Liquidia Corp)|Rasio rega marang pendapatan Galapagos Genomics (GLPG)|ANIP (ANI Pharmaceuticals Corp) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S MNKD (MannKind Corporation)|amphastar.com (AMPH) - Rega marang dodolan|Pacira BioSciences, Inc. - Multiplikator P/S|Rasio rega marang dodolan SPRY|Theravance (TBPH) - Rasio rega marang pendapatan|Rega marang dodolan Aquestive Corp (AQST)|Rasio rega marang pendapatan scPharmaceuticals, Inc.|TECX: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Tonix Pharmaceuticals Holding Corp. (TNXP)|Kapitalisasi marang pendapatan sxtchina.com SXTC|Eupraxia Pharmaceuticals Inc. - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan BHST|EXOZ - Rasio rega marang pendapatan|ORMP: Rasio rega marang pendapatan|ENTX (enterabio.com) - Kapitalisasi marang pendapatan|HYFT: Kapitalisasi marang volume dodolan|ABVC (ABVC BioPharma Inc) - Multiplikator P/S|Rasio kapitalisasi marang pendapatan CPIX (Cumberland Corp)|Kapitalisasi marang pendapatan QNTM (Quantum BioPharma Ltd)|Koefisien rega marang pendapatan fibrogen.com|Rasio rega marang pendapatan Telomir Pharmaceuticals, Inc. TELO|RANI (Rani Therapeutics Holdings) - Rasio rega marang dodolan|SNYR - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan RLYB (Rallybio Corporation)|LEXX: Multiplikator P/S|Rasio rega marang dodolan PULM (pulmatrix.com)|Kapitalisasi marang pendapatan PTHL|Rasio kapitalisasi marang pendapatan APM (Aptorum)|Rasio rega marang pendapatan Lyra Therapeutics, Inc (LYRA)|IBO: Rasio rega marang dodolan|Multiplikator P/S TNFA (TNF Pharmaceuticals, Inc.)|Rasio kapitalisasi pasar marang pendapatan YCBD|Auris Medical - Multiplikator P/S|LIPO - Multiplikator P/S|Optinose (OPTN) - Rasio rega marang pendapatan|Pieris Pharma - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Procaps Group S.A.|Kapitalisasi marang pendapatan petrospharma.com (PTPI)|Multiplikator P/S QLI|Multiplikator P/S Acelyrin Inc. (SLRN)|TFF Pharma - Kapitalisasi marang pendapatan
